Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues
Identifieur interne : 001346 ( Main/Exploration ); précédent : 001345; suivant : 001347Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues
Auteurs : Magdalena Czarnecka-Operacz [Pologne] ; Dorota Jenerowicz [Pologne]Source :
- JDDG: Journal der Deutschen Dermatologischen Gesellschaft [ 1610-0379 ] ; 2012-03.
English descriptors
- Teeft :
- Acad dermatol, Acad dermatol venereol, Adult patients, Allergy, Allergy clin immunol, Arch dermatol, Atopic, Atopic dermatitis, Atopic dermatitis patients, Atopic inflammation, Atopic skin, Authors journal compilation blackwell verlag gmbh, Berlin jddg review, Calcineurin, Calcineurin inhibitors, Clin dermatol, Clinical presentation, Clinical trials, Corticosteroid, Corticosteroid phobia, Daily application, Dermatitis, Dermatol, Dermatology, Erosive mucosal lichen planus, Generalized leukemic erythroderma, Important issue, Inflammation, Inhibitor, Intertriginous areas, Jddg, Lamellar ichthyosis, Lymphoma, Malignancy, Mast cell degranulation, Mast cells, Medical science, Netherton syndrome, Nonmelanoma skin cancer, Ointment, Oral acetylsalicylic acid, Organ transplant patients, Pharmacokinetic studies, Pimecrolimus, Pimecrolimus cream, Position statement, Potential photocarcinogenicity, Potential safety risks, Proactive, Proactive approach, Proactive therapy, Proactive treatment, Problem zones, Proper education, Pyoderma gangrenosum, Safety concerns, Safety profile, Severe atopic dermatitis, Severe pruritus, Side effects, Skin barrier, Skin cancer, Skin cancers, Skin carcinogenesis, Skin disorder, Skin lesions, Staphylococcus aureus, Systemic absorption, Systemic circulation, Tacrolimus, Tacrolimus ointment, Topical, Topical application, Topical calcineurin inhibitors, Topical corticosteroids, Topical tacrolimus, Topical treatment.
Abstract
Atopic dermatitis is a common chronic skin disorder whose management is complex. Topical corticosteroids have been the mainstay of atopic dermatitis treatment for more than 50 years but have multiple side effects. Topical calcineurin inhibitors including tacrolimus and pimecrolimus are safe and efficacious in atopic dermatitis. In 2005 the FDA issued “black box” warnings for pimecrolimus cream and tacrolimus ointment because of potential safety risks, including skin cancers and lymphomas. However, these concerns are not supported by current data. Topical calcineurin inhibitors are particularly indicated for treating patients with atopic dermatitis in whom topical corticosteroid therapy cannot be employed or may cause irreversible side effects. They can be used advantageously in problem zones. A novel regimen of proactive treatment has been shown to prevent, delay and reduce exacerbations of atopic dermatitis. Therapy with topical calcineurin inhibitors should be managed by an experienced specialist and each patient should receive proper education on how to use them and what possible unwanted effects may be expected.
Url:
DOI: 10.1111/j.1610-0387.2011.07791.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B46
- to stream Istex, to step Curation: 000B30
- to stream Istex, to step Checkpoint: 000407
- to stream Main, to step Merge: 001348
- to stream Main, to step Curation: 001346
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues</title><author><name sortKey="Czarnecka Peracz, Magdalena" sort="Czarnecka Peracz, Magdalena" uniqKey="Czarnecka Peracz M" first="Magdalena" last="Czarnecka-Operacz">Magdalena Czarnecka-Operacz</name></author><author><name sortKey="Jenerowicz, Dorota" sort="Jenerowicz, Dorota" uniqKey="Jenerowicz D" first="Dorota" last="Jenerowicz">Dorota Jenerowicz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AA855AEEEB7D646FA4A0DBE1EFB75641D5AB8D98</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1610-0387.2011.07791.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-LPR31BQS-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000B46</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B46</idno><idno type="wicri:Area/Istex/Curation">000B30</idno><idno type="wicri:Area/Istex/Checkpoint">000407</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000407</idno><idno type="wicri:doubleKey">1610-0379:2012:Czarnecka Peracz M:topical:calcineurin:inhibitors</idno><idno type="wicri:Area/Main/Merge">001348</idno><idno type="wicri:Area/Main/Curation">001346</idno><idno type="wicri:Area/Main/Exploration">001346</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues</title><author><name sortKey="Czarnecka Peracz, Magdalena" sort="Czarnecka Peracz, Magdalena" uniqKey="Czarnecka Peracz M" first="Magdalena" last="Czarnecka-Operacz">Magdalena Czarnecka-Operacz</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Dermatology, Poznan´ University of Medical Science, Poznań</wicri:regionArea><wicri:noRegion>Poznań</wicri:noRegion></affiliation></author><author><name sortKey="Jenerowicz, Dorota" sort="Jenerowicz, Dorota" uniqKey="Jenerowicz D" first="Dorota" last="Jenerowicz">Dorota Jenerowicz</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Dermatology, Poznan´ University of Medical Science, Poznań</wicri:regionArea><wicri:noRegion>Poznań</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">JDDG: Journal der Deutschen Dermatologischen Gesellschaft</title><title level="j" type="alt">JDDG JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT</title><idno type="ISSN">1610-0379</idno><idno type="eISSN">1610-0387</idno><imprint><biblScope unit="vol">10</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="167">167</biblScope><biblScope unit="page" to="172">172</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2012-03">2012-03</date></imprint><idno type="ISSN">1610-0379</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1610-0379</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad dermatol</term><term>Acad dermatol venereol</term><term>Adult patients</term><term>Allergy</term><term>Allergy clin immunol</term><term>Arch dermatol</term><term>Atopic</term><term>Atopic dermatitis</term><term>Atopic dermatitis patients</term><term>Atopic inflammation</term><term>Atopic skin</term><term>Authors journal compilation blackwell verlag gmbh</term><term>Berlin jddg review</term><term>Calcineurin</term><term>Calcineurin inhibitors</term><term>Clin dermatol</term><term>Clinical presentation</term><term>Clinical trials</term><term>Corticosteroid</term><term>Corticosteroid phobia</term><term>Daily application</term><term>Dermatitis</term><term>Dermatol</term><term>Dermatology</term><term>Erosive mucosal lichen planus</term><term>Generalized leukemic erythroderma</term><term>Important issue</term><term>Inflammation</term><term>Inhibitor</term><term>Intertriginous areas</term><term>Jddg</term><term>Lamellar ichthyosis</term><term>Lymphoma</term><term>Malignancy</term><term>Mast cell degranulation</term><term>Mast cells</term><term>Medical science</term><term>Netherton syndrome</term><term>Nonmelanoma skin cancer</term><term>Ointment</term><term>Oral acetylsalicylic acid</term><term>Organ transplant patients</term><term>Pharmacokinetic studies</term><term>Pimecrolimus</term><term>Pimecrolimus cream</term><term>Position statement</term><term>Potential photocarcinogenicity</term><term>Potential safety risks</term><term>Proactive</term><term>Proactive approach</term><term>Proactive therapy</term><term>Proactive treatment</term><term>Problem zones</term><term>Proper education</term><term>Pyoderma gangrenosum</term><term>Safety concerns</term><term>Safety profile</term><term>Severe atopic dermatitis</term><term>Severe pruritus</term><term>Side effects</term><term>Skin barrier</term><term>Skin cancer</term><term>Skin cancers</term><term>Skin carcinogenesis</term><term>Skin disorder</term><term>Skin lesions</term><term>Staphylococcus aureus</term><term>Systemic absorption</term><term>Systemic circulation</term><term>Tacrolimus</term><term>Tacrolimus ointment</term><term>Topical</term><term>Topical application</term><term>Topical calcineurin inhibitors</term><term>Topical corticosteroids</term><term>Topical tacrolimus</term><term>Topical treatment</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Atopic dermatitis is a common chronic skin disorder whose management is complex. Topical corticosteroids have been the mainstay of atopic dermatitis treatment for more than 50 years but have multiple side effects. Topical calcineurin inhibitors including tacrolimus and pimecrolimus are safe and efficacious in atopic dermatitis. In 2005 the FDA issued “black box” warnings for pimecrolimus cream and tacrolimus ointment because of potential safety risks, including skin cancers and lymphomas. However, these concerns are not supported by current data. Topical calcineurin inhibitors are particularly indicated for treating patients with atopic dermatitis in whom topical corticosteroid therapy cannot be employed or may cause irreversible side effects. They can be used advantageously in problem zones. A novel regimen of proactive treatment has been shown to prevent, delay and reduce exacerbations of atopic dermatitis. Therapy with topical calcineurin inhibitors should be managed by an experienced specialist and each patient should receive proper education on how to use them and what possible unwanted effects may be expected.</div></front></TEI><affiliations><list><country><li>Pologne</li></country></list><tree><country name="Pologne"><noRegion><name sortKey="Czarnecka Peracz, Magdalena" sort="Czarnecka Peracz, Magdalena" uniqKey="Czarnecka Peracz M" first="Magdalena" last="Czarnecka-Operacz">Magdalena Czarnecka-Operacz</name></noRegion><name sortKey="Jenerowicz, Dorota" sort="Jenerowicz, Dorota" uniqKey="Jenerowicz D" first="Dorota" last="Jenerowicz">Dorota Jenerowicz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001346 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001346 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AA855AEEEB7D646FA4A0DBE1EFB75641D5AB8D98
|texte= Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues
}}
| This area was generated with Dilib version V0.6.33. |  |